Loading...
•
Mar 31, 2022
Ironwood Pharmaceuticals Q1 2022 Earnings Report
Reported first quarter 2022 results and maintained full year 2022 financial guidance.
Key Takeaways
Ironwood Pharmaceuticals reported its first quarter 2022 results, featuring an 11% year-over-year increase in LINZESS® prescription demand and U.S. LINZESS® net sales of $232 million, an 8% increase year-over-year. The company reported total revenue of $98 million, GAAP net income of $39 million, and adjusted EBITDA of $58 million, ending the quarter with $593 million in cash and cash equivalents.
LINZESS prescription demand growth increased 11% year-over-year.
LINZESS U.S. net sales reached $232 million, an increase of 8% year-over-year.
Total revenue was reported at $98 million, with U.S. LINZESS collaboration revenue of $94 million.
GAAP net income was $39 million and adjusted EBITDA was $58 million; the quarter ended with $593 million in cash and cash equivalents.
Forward Guidance
Ironwood Pharmaceuticals maintained its full year 2022 financial guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...